{"id":"W1974674483","doi":"10.1182/blood-2006-04-015560","title":"A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":413,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Myeloid leukemia; Medicine; Internal medicine; Fms-Like Tyrosine Kinase 3; Tyrosine-kinase inhibitor; Chemotherapy; Adverse effect; Oncology; Pharmacology; Leukemia; Chemotherapy regimen; Cancer; Biology; Mutation","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001646588,0.0003854419,0.0007682107,0.0001225066,0.0001755184,0.00002592109,0.0001835937,0.0001997154,0.00005311107],"category_scores_gemma":[0.000396316,0.0002296006,0.0003812943,0.000232638,0.0002459296,0.00007011835,0.00004837281,0.0001779111,0.000007677048],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004957649,"about_ca_system_score_gemma":0.001234208,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002483476,"about_ca_topic_score_gemma":0.00009894035,"domain_scores_codex":[0.997756,0.00004250314,0.0006323559,0.0005161437,0.0005043942,0.0005485803],"domain_scores_gemma":[0.9972055,0.0004922966,0.0003569108,0.0006421154,0.001155913,0.0001472432],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.817956,0.03682878,0.003865392,0.0006816083,0.00681538,0.0001382823,0.002889372,0.00004092909,0.04857442,0.0002661219,0.05009153,0.03185216],"study_design_scores_gemma":[0.6278931,0.01660444,0.0009397722,0.0001689689,0.001233527,0.0000354346,0.000130371,0.0001759712,0.3447972,0.00009453986,0.007683102,0.0002435198],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854622,0.00004982691,0.0002250312,0.003116111,0.0001618255,0.01007053,0.0007184701,0.00005165278,0.0001443706],"genre_scores_gemma":[0.9914669,0.00004026292,0.002458704,0.0009980884,0.0007864646,0.001303474,0.0003859295,0.0001193841,0.002440788],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2962228,"threshold_uncertainty_score":0.936284,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02650563510070308,"score_gpt":0.3123375602894287,"score_spread":0.2858319251887256,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}